The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in the brain connectivity patterns of severe and moderate acute brain injury patients with suppression of consciousness. The main questions it aims to answer are:
Does the antiseizure medication reduce the functional connectivity of seizure networks, as identified by resting state functional MRI (rs-fMRI), within this specific target population?
What is the prevalence of seizure networks in patients from the target population, both with EEG suggestive and not suggestive of epileptogenic activity?
Participants will have a rs-fMRI and those with seizure networks will receive treatment with two antiseizure medications and a post-treatment rs-fMRI. Researchers will compare the pretreatment and post-treatment rs-fMRIs to see if there are changes in the participant's functional connectivity including seizure networks and typical resting state networks.

开始日期2023-11-20

申办/合作机构

The University of North Carolina at Chapel Hill

NCT03586089 / TerminatedN/AIIT

PHENObarbital for the MANagement of Severe Acute ALcohol Withdrawal Syndrome (PHENOMANAL): a Prospective Randomized Feasibility Study.

Severe acute alcohol withdrawal syndrome is a potentially life-threatening condition characterized by agitation, confusion, abnormal heart rhythms and seizures. Typically, clinicians treat the symptoms of alcohol withdrawal with a class of medications known as benzodiazepines (e.g., Valium). These medications have a short duration of activity and require repeated administration, often every hour or less, to reduce the symptoms of alcohol withdrawal. Many patients suffer complications related to inadequate treatment of alcohol withdrawal (e.g., abnormal heart rhythms, aspiration, seizures) resulting in admission to an intensive care unit and prolonged hospital stay, all of which increase healthcare costs. Although alcohol withdrawal is common, especially among disadvantaged (e.g., homeless) patients, limited funding is available to advance the care of patients suffering from alcohol withdrawal. A safe and effective treatment for severe alcohol withdrawal would benefit patients and our healthcare system.
Phenobarbital is an inexpensive, commonly available medication that is typically used to treat seizures. A key advantage of phenobarbital is that its calming effect lasts for a long period of time and it can be given as a 'one-time-dose' intravenously, so that it both prevents and treats withdrawal symptoms and reduces the need for repeated benzodiazepines. Through better symptom control, phenobarbital is expected to reduce the costs and complications of alcohol withdrawal. At present, physicians rarely use phenobarbital for this purpose, and additional research is needed for this medication to become part of routine care in clinical practice.
The PHENOMANAL pilot trial will assess safety and whether clinicians can administer a single dose of phenobarbital intravenously, in addition to benzodiazepines, compared to benzodiazepines alone for treating patients with severe alcohol withdrawal. This information will inform the design of a larger clinical trial. For patients, the PHENOMANAL trial has the potential to revolutionize how patients suffering from severe alcohol withdrawal are treated. For society and the healthcare system, phenobarbital is expected to reduce the complications and costs associated with severe alcohol withdrawal.

开始日期2021-06-11

申办/合作机构

Unity Health Toronto

NCT04320940 / Terminated临床3期

A Randomized, Double-Blind, Controlled Study to Assess the Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of phenobarbital sodium injection in neonates who have suffered from electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show intravenous phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower dose.

开始日期2021-03-12

申办/合作机构

NEMA Research, Inc.

100 项与苯巴比妥钠相关的临床结果

登录后查看更多信息

100 项与苯巴比妥钠相关的转化医学

登录后查看更多信息

100 项与苯巴比妥钠相关的专利（医药）

登录后查看更多信息

545

项与苯巴比妥钠相关的文献（医药）

2024-11-01·Journal of Applied Toxicology

Hepatic enzyme induction and its potential effect on thyroid hormone metabolism in the metamorphosing tadpole of Xenopus laevis (African clawed frog)

Article

作者: Yamaguchi, Takafumi ; Fujisawa, Takuo ; Wada, Kohei ; Tanaka, Hitoshi

AbstractHepatic enzyme induction, an inherent defense system against xenobiotics, is known to simultaneously affect endocrine system functions in mammals under specific conditions, particularly thyroid hormone (TH) regulation. While this phenomenon has been studied extensively, the pathway leading to this indirect thyroid effect in mammals has unclear applicability to amphibians, despite the importance of amphibian species in assessing thyroid‐disruptive chemicals. Here, we investigated the effects of three well‐known mammalian enzyme inducers—β‐naphthoflavone (BNF), pregnenolone carbonitrile (PCN), and sodium phenobarbital (NaPB)—on the gene expression of phase‐I and phase‐II metabolizing enzymes in Xenopus laevis tadpoles. Waterborne exposure to BNF and PCN significantly induced the expression of both phase‐I (cytochrome P450, CYP) and phase‐II enzymes (UDP‐glucuronosyltransferase, UGT and sulfotransferase, SULT), but in different patterns, while NaPB exposure induced CYP2B expression without affecting phase‐II enzymes in tadpoles, in contrast to mammals. Furthermore, an ex vivo hepatic enzyme activity assay confirmed that BNF treatment significantly increased phase‐II metabolic activity (glucuronidation and sulfation) toward TH. These results suggest the potential for certain mammalian enzyme inducers to influence TH clearance in X. laevis tadpoles. Our findings provide insights into the profiles of xenosensing activity and enzyme induction in amphibians, which can facilitate a better understanding of the mechanisms of indirect effects on the thyroid system via hepatic enzyme induction in nonmammalian species.

2024-08-20·Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

[A case of recurrent convulsions caused by acute sulfuryl fluoride gas poisoning].

Article

作者: Su, C H ; Wang, R ; Li, Z H ; Zhang, Q B ; Zhang, Y G

硫酰氟是一种具有渗透性强、低温使用方便、无腐蚀性等特点的杀灭粮食害虫、对白蚁有较强杀伤力的农药。急性硫酰氟中毒时，患者可见惊厥反复发作、阵法棘波或高幅棘波等癫痫样脑电图异常等临床表现。本文报道1例以惊厥为主的精神系统症状的硫酰氟中毒患者，给予地塞米松、苯巴比妥钠等临床治疗后，患者治愈出院。.

2024-07-01·Biomaterials

Optical controlled and nuclear targeted CECR2 competitor to downregulate CSF-1 for metastatic breast cancer immunotherapy

Article

作者: Cen, Yi ; Chen, Ying ; Yu, Baixue ; Yan, Ni ; Li, Shiying ; Yan, Mengyi ; Chen, Xiayun ; Cheng, Hong ; Li, Xinxuan

The crosstalk between breast cancer cells and tumor associated macrophages (TAMs) greatly contributes to tumor progression and immunosuppression. In this work, cat eye syndrome chromosome region candidate 2 (CECR2) is identified to overexpress in breast cancer patients, which can recognize v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) and activate nuclear factor κB (NF-κB) to release colony stimulating factor-1 (CSF-1). Pharmacological inhibition of CECR2 by the bromodomain competitor (Bromosporine, Bro) can downregulate CSF-1 to inhibit M2 type TAMs. To amplify the immunotherapeutic effect, a chimeric peptide-based and optical controlled CECR2 competitor (designated as N-PB) is constructed to enhance the nuclear targeted delivery of Bro and initiate an immunogenic cell death (ICD). In vivo results indicate a favorable breast cancer targeting ability and primary tumor suppression effect of N-PB under optical irradiation. Importantly, N-PB downregulates CSF-1 by competitive inhibition of CECR2 and NF-κB(RelA) interactions, thus inhibiting immunosuppressive M2-like TAMs while improving the antitumorigenic M1-like phenotype. Ultimately, the systemic anti-tumor immunity is activated to suppress the metastatic breast cancer in an optical controlled manner. This study provides a promising therapeutic target and reliable strategy for metastatic breast cancer treatment by interrupting immunosuppressive crosstalk between tumor cells and macrophages.

项与苯巴比妥钠相关的新闻（医药）

2023-09-19

·Outsourcing Pharma

Pharmanovia acquires 11 of Sanofi's CNS brands expanding its global reach

Spanning four therapy areas – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic, the brands fall within the unmet ongoing needs sector associated with CNS disorders. Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients. The acquired brands include Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium. Frisium may also be used as adjunctive therapy in epilepsy. Phenobarbital with the brand name Gardenal is used as an anti-convulsant to treat all forms of epilepsy except absence seizures. Cyamemazine (brand name Tercian) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant. Prochlorperazine (brand name Stemetil) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety. Dr James Burt, Pharmanovia CEO, said: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium and Gardenal, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. “We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.” It should be noted that not all of the acquired treatments have been approved in every market and local indications can be checked, for example, Tercian is currently only available in France. Pharmanovia is listed as a lifecycle management healthcare company and focuses on making medicines to improve the lives of patients globally. The company says this is achieved through enhancing already established medicines by ‘rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.’ Sanofi says it is dedicated to transforming the practice of medicine ‘by working to turn the impossible into the possible’. It aims to provide potentially life-changing treatment options and life-saving vaccine protection to millions of people around the world.

并购上市批准

2023-09-18

·BioSpace

Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi

Deal sees Pharmanovia acquire 11 brands within CNS, including Frisium® (clobazam) and Gardenal® (phenobarbital) Portfolio available in 60+ markets and deepens our CNS footprint in Brazil, South Africa, France and Italy Strong CNS franchise fits with Pharmanovia’s existing neurology portfolio and commercial capabilities BASILDON, England--(BUSINESS WIRE)-- PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY This press release features multimedia. View the full release here: James Burt, CEO, Pharmanovia (Photo: Business Wire) Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. The brands span four therapy areas of ongoing unmet need associated with CNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.1 The acquired brands include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® may also be used as adjunctive therapy in epilepsy.1 Phenobarbital (brand: Gardenal®*) is used as an anti-convulsant to treat all forms of epilepsy except absence seizures.2 Cyamemazine (brand: Tercian®*†) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant.3 Prochlorperazine (brand: Stemetil®*) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety.4,5 Dr James Burt, Pharmanovia CEO, commented: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium® and Gardenal®, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.” “Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.” -Ends- Notes to editors *Not all indications are approved in every market. For local indications it is advised to check the local approved label. †Tercian® is only available in France. About Pharmanovia Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships. Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology. For more information about Pharmanovia, please visit About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: to chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. References 1 - Frisium Summary of Product Characteristics, – last accessed 11.9.2023 2 - Phenobarbital Sodium Injection Summary of Product Characteristics, - last accessed 11.9.2023 3 - Terican Summary of Product Characteristics, – last accessed 11.9.2023 4 - Stemetil Injection Summary of Product Characteristics, - last accessed 11.9.2023 5 - Stemetil Tablets Summary of Product Characteristics, - last accessed 11.9.2023 COR2023PR00207 – Date of Preparation – 14.9.2023 View source version on businesswire.com: Contacts Alison Dyson, Director of Communications, Pharmanovia +44 7442 256310/alison.dyson@pharmanovia.com or pharmanovia@67health.co.uk Source: Pharmanovia Smart Multimedia Gallery Photo James Burt, CEO, Pharmanovia (Photo: Business Wire) Logo View this news release and multimedia online at:

并购

2022-11-26

·药智网

新药速递 | 2022年11月获批新药一览

看点1.全球首款延缓1型糖尿病创新疗法获FDA批准2.FDA批准首个B型血友病基因疗法上市3.三款国产1类创新药获NMPA批准上市2022年11月，全球多款创新疗法获批上市，包括基因疗法、ADC、单抗及多款小分子药物，适应症涵盖1型糖尿病、B型血友病、抑郁症、癫痫及多种癌症。01 美国FDA批准的新药美国FDA在2022年11月批准了5款新药上市，包括药品审评和研究中心（CDER）批准的2款新分子实体，一款联合疗法和一款改良型新药，以及生物制品审评和研究中心（CBER）批准的一款基因疗法。表1 2022年11月美国FDA批准的新药数据来源：美国FDA官网ELAHEREELAHERE (mirvetuximab soravtansine-gynx) 是ImmunoGen公司开发的一款针对FRα（一种在卵巢癌中高度表达的细胞表面蛋白）的first-in-class ADC，获FDA加速批准用于治疗叶酸受体α（FRα）阳性、铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年患者，这些患者之前接受过一至三种全身治疗方案。这是美国FDA批准的首个用于铂耐药疾病的ADC，此次获批是基于关键性3期临床试验SORAYA的结果。结果显示，在106例肿瘤表达高水平FRα的含铂药物耐药卵巢癌患者中，客观缓解率（ORR）为31.7%（95% CI：22.9%，41.6%），包括5例完全缓解（CR）；中位DOR为6.9个月（95%CI:5.6，9.7）。在中国，2020年华东医药以4000万美元的首付款，至多2.65亿美元的里程碑付款，获得该药在中国大陆、香港、澳门和台湾地区独家临床开发和商业化权益。TZIELDTZIELD（teplizumab-mzwv）是Provention Bio公司开发的一种用于静脉注射的抗CD3单抗，获批用于延缓1型糖尿病特定高危人群的疾病进程。这是首款也是唯一一款获批的能延缓1型糖尿病发作的药物，它从根本上改变了疾病的过程，而不仅仅是治疗其症状。FDA此次批准是基于一项名为TN-10的临床试验。在该项研究中，76名2期1型糖尿病患者接受了Tzield的安全性和疗效评估。结果显示，在51个月的中位随访中，接受Tzield的44名患者中有45%后来被诊断为3期1型糖尿病，而接受安慰剂的32名患者中有72%被诊断为3期糖尿病。此外，接受Tzield的病人从随机到诊断为3期1型糖尿病的中位时间是50个月，接受安慰剂的病人是25个月。这些数据表明TZIELD的治疗可以显著延缓1型糖尿病的病情进展。IMJUDOImjudo (tremelimumab)是阿斯利康开发的一款抗CTLA-4抗体，Imfinzi (durvalumab, 度伐利尤单抗)是一款抗PD-L1单抗。上个月，FDA已批准Imjudo+Imfinzi用于不可切除的肝细胞癌。此次FDA再次批准Imjudo+Imfinzi+化疗，用于不携带表皮生长因子受体（EGFR）突变或间变性淋巴瘤激酶（ALK）融合的转移性非小细胞肺癌（NSCLC）成年患者。SEZABYSEZABY (注射用苯巴比妥钠粉)是太阳制药开发的一款苯巴比妥钠的新型制剂，是一种无苄醇、无丙二醇苯巴比妥钠粉。该药曾被美国FDA授予孤儿药资格，用于治疗新生儿癫痫。本次获批使该药成为美国FDA批准的第一个也是唯一一个专门用于治疗新生儿癫痫发作的产品。 HEMGENIXHEMGENIX(etranacogene dezaparrvovec drlb)是uniQure和CSL共同开发的一种一次性基因疗法，用于治疗目前使用凝血因子IX预防治疗成人B型血友病，或目前或历史上有危及生命的出血，或有反复严重的自发性出血发作。这是全球首个获批的针对血友病B的基因疗法。HEMGENIX使用AAV5载体将表达凝血因子IX Padua变体的转基因递送到肝脏，使身体持续产生因子IX，降低符合条件的血友病B患者的异常出血率。此前，该疗法曾获美国FDA授予突破性疗法认定、孤儿药资格以及优先审评资格。值得一提的是，该药定价350万美元，是目前美国最贵的药物之一。02NMPA批准的新药2022年11月，中国国家药品监督管理局（NMPA）批准了3款1类新药，均为小分子化药。表2 2022年11月NMPA批准的国产新药数据来源：NMPA官网、药智数据盐酸托鲁地文拉法辛缓释片盐酸托鲁地文拉法辛(盐酸安舒法辛缓释片，LY03005)获国家药监局批准上市，用于抑郁症的治疗。这是中国首个自主研发并拥有自主知识产权用于治疗抑郁症的化药1类创新药。该药由山东绿叶制药开发，公开资料显示，该药的抗抑郁作用可能与通过抑制5-羟色胺(5-HT)、去甲肾上腺素(NE)的再摄取而增强中枢神经系统的5-HT、NE效应有关。林普利塞片林普利塞片（linperlisib，商品名：因他瑞）获国家药监局附条件批准上市，用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。这是我国首个获批上市的高选择性PI3Kδ抑制剂。该药由上海璎黎药业研发，恒瑞医药于2021年2月对璎黎药业进行2000万美元股权投资（占总股本6.67%），并获得了林普利塞在大中华地区的联合开发权益以及排他性独家商业化权益。此前，林普利塞曾获得NMPA颁发的用于治疗R/R FL的突破性疗法认定，以及美国FDA颁发的FL、慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）和T细胞淋巴瘤适应症的三项孤儿药资格认定。在2022年公布的林普利塞治疗R/R FL患者的中国II期临床试验最新数据显示，林普利塞治疗R/R FL患者的有效率接近百分之八十，并表现出可控的安全性。甲苯磺酰胺注射液甲苯磺酰胺注射液获国家药监局批准上市，用于严重气道阻塞的中央型非小细胞肺癌的治疗。这是我国首次批准的经纤维支气管镜肿瘤内局部注射的化学消融药物，也是首个适应症为减轻中央型非小细胞肺癌（NSCLC）成人患者的重度气道阻塞的药物，填补了呼吸介入药物治疗的空白。该药由钟南山院士挂帅研发，最早在2003年11月21日递交临床申请，原申报临床的申请人为北京健达康新药开发有限公司。随后经过一系列知识产权和所有权的转移，最终由天津红日亚药业进行上市申报和生产。其上市申请在2018年获得CDE受理，在经历了将近5年的审评后终于获批上市。除了国产新药，本月NMPA还批准了两款进口新药，详情见下表：表3 2022年11月NMPA批准的进口新药数据来源：NMPA官网、药智数据帕博利珠单抗注射液（商品名：可瑞达®️）是默沙东开发的一款PD-1单抗，本月在国内获批了一项新适应症：联合化疗新辅助治疗并在手术后继续帕博利珠单抗单药辅助治疗，用于经充分验证的检测评估肿瘤表达PD-L1（综合阳性评分（CPS）≥20）的早期高危三阴性乳腺癌（TNBC）患者的治疗。至此，可瑞达已在国内获批10项适应症，涵盖黑色素瘤、肺癌、食管癌、头颈鳞癌、结直肠癌、食管癌、肝细胞癌、乳腺癌等多种实体瘤。八氟丙烷脂质微球注射液是兰索斯医学影像公司于2001年推出的一款超声造影剂产品。2012年，华润双鹤与兰索斯公司合作，华润双鹤在十五年协议期间将作为八氟丙烷脂质微球注射液在我国独家经销商。本品于2016年2月在国内获批临床，2020年6月首次在国内申报上市，本次终于获批上市。12月，又将有哪些新药获得批准？欢迎关注博药微信公众号，小编将为您持续跟踪报道。03 推荐阅读 ⭐ 新药速递 | 2022年10月获批的新药一览来源 | 博药（药智网获取授权转载）撰稿 | 森林责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。— Tips —如果您有医药行业相关的线索或对医药政策、研发创新、资本市场、行业发展有深度观察欢迎投稿给我们马老师 18323856316（同微信）邮箱：maxuelian@yaozh.com 阅读原文，是受欢迎的文章哦

临床3期上市批准引进/卖出抗体药物偶联物

100 项与苯巴比妥钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00701	苯巴比妥钠	N03AA02	DB01174

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新生儿癫痫	美国	Sun Pharmaceutical Industries, Inc.	2022-11-17
婴儿痉挛	日本	Nobelpharma Co., Ltd.	2008-10-16
高胆红素血症	中国	佑华制药（乐山）有限公司	1981-01-01
高胆红素血症	中国	天津金耀药业有限公司	1981-01-01
高胆红素血症	中国	远大医药集团	1981-01-01
高胆红素血症	中国	地奥集团成都药业股份有限公司	1981-01-01
癫痫发作	中国	远大医药集团	1981-01-01
癫痫发作	中国	佑华制药（乐山）有限公司	1981-01-01
癫痫发作	中国	天津金耀药业有限公司	1981-01-01
癫痫发作	中国	地奥集团成都药业股份有限公司	1981-01-01
镇静	日本	Takata Seiyaku Co., Ltd.	1980-03-04
镇静	日本	Hisamitsu Pharmaceutical Co., Inc.	1980-03-04
热性惊厥	日本	Takata Seiyaku Co., Ltd.	1980-03-04
热性惊厥	日本	Hisamitsu Pharmaceutical Co., Inc.	1980-03-04
入睡和睡眠障碍	日本	Takata Seiyaku Co., Ltd.	1980-03-04
入睡和睡眠障碍	日本	Hisamitsu Pharmaceutical Co., Inc.	1980-03-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新生儿癫痫	申请上市	美国	Sun Pharma Advanced Research Co. Ltd.	2022-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04320940 (CTgov)	临床3期	新生儿癫痫	4	Phenobarbital Sodium Injection (Phenobarbital Sodium Injection 20mg)	襯鏇構簾餘選鹹餘糧築(積積鑰願鏇醖網範構鑰) = 鹹憲壓艱遞願壓繭構廠願構鹹衊窪膚網壓築壓 (醖範鹽構醖膚獵淵鹹範, 範膚夢鏇構網獵鏇遞鏇 ~ 顧積選齋壓艱鹹築窪鹹) 更多	-	2023-10-26
				Phenobarbital Sodium Injection (Phenobarbital Sodium Injection 40mg)	襯鏇構簾餘選鹹餘糧築(積積鑰願鏇醖網範構鑰) = 膚製鹽淵淵觸鏇憲窪艱願構鹹衊窪膚網壓築壓 (醖範鹽構醖膚獵淵鹹範, 遞觸艱製繭壓鹽膚齋願 ~ 積壓顧淵簾餘鏇鏇夢窪) 更多